CD133 antigen expression in ovarian cancer.
CD133 antigen expression in ovarian cancer.
复制标题
DOI：
10.1186/1471-2407-9-221
复制
发表时间：
2009-07-07
期刊：
影响因子：
3.8
通讯作者：
Scambia G
中科院分区：
文献类型：
--
作者：
Ferrandina G;Martinelli E;Petrillo M;Prisco MG;Zannoni G;Sioletic S;Scambia G
近年来，肿瘤干细胞在恶性实体瘤发生发展中的作用受到了广泛关注。由于CSC能够广泛增殖和自我更新，从而维持肿瘤生长，因此通过其抗原谱鉴定CSC可能具有相关的临床意义。在这种情况下，CD 133抗原已被证明是一个标志物的肿瘤细胞的干细胞的功能，在一些人类恶性肿瘤。该研究的目的是调查在一个大型的单一机构系列的卵巢癌患者中，化学评估的CD 133表达的临床作用。该研究纳入了坎波巴索和罗马天主教大学妇科肿瘤科收治的160例病例。通过单克隆小鼠抗CD 133 -1抗体（克隆CD 133 Miltenyi biotec）鉴定CD 133抗原。在整个系列中，在50/160（31.2%）例病例中观察到CD 133阳性肿瘤细胞。在30/50（60.0%）的CD 133阳性肿瘤中发现弥漫性胞浆模式，而在20/50（40.0%）的CD 133阳性肿瘤中发现顶端胞浆模式。截至2008年9月，中位随访时间为37个月（范围：2-112）。在随访期间，分别在123例（76.9%）和88例（55.0%）病例中观察到疾病进展和死亡。CD 133表达阴性（中位TTP = 23个月）与CD 133表达阳性（中位TTP = 24个月）病例之间的TTP无差异（p值= 0.3）。OS获得了类似的结果。当根据CD 133表达模式考虑TTP和OS曲线时，记录了弥漫性胞浆型与顶端胞浆型病例预后更差的趋势，尽管未达到统计学显著性。CD 133表达的免疫组化评估似乎不能提供卵巢癌患者的额外预后信息。CD 133免疫反应的不同模式的作用值得在更大的系列中进一步研究。
Much attention has been recently focused on the role of cancer stem cells (CSCs) in the initiation and progression of solid malignancies. Since CSCs are able to proliferate and self-renew extensively, thus sustaining tumor growth, the identification of CSCs through their antigenic profile might have relevant clinical implications. In this context, CD133 antigen has proved to be a marker of tumor cells with stemness features in several human malignancies. The aim of the study was to investigate the clinical role of the immunohistochemically assessed expression of CD133 in a large single Institution series of ovarian cancer patients. The study included 160 cases admitted to the Gynecologic Oncology Unit, Catholic University of Campobasso and Rome. CD133 antigen was identified by the monoclonal mouse anti-CD133-1 antibody (clone CD133 Miltenyi biotec). In the overall series CD133 positive tumor cells were observed in 50/160 (31.2%) cases. A diffuse cytoplasmic pattern was identified in 30/50 (60.0%), while an apical cytoplasmic pattern was found in 20/50 (40.0%) of CD133 positive tumors. As of September 2008, the median follow up was 37 months (range: 2–112). During the follow up period, progression and death of disease were observed in 123 (76.9%), and 88 (55.0%) cases, respectively. There was no difference in TTP between cases with negative (median TTP = 23 months) versus positive CD133 expression (median TTP = 24 months) (p value = 0.3). Similar results were obtained for OS. When considering the TTP and OS curves according to the pattern of CD133 expression, a trend to a worse prognosis for cases with diffuse cytoplasmic versus the apical cytoplasmic pattern was documented, although the statistical significance was not reached. The immunohistochemical assessment of CD133 expression seems not to provide additional prognostic information in ovarian cancer patients. The role of the different pattern of CD133 immunoreaction deserves further investigation in a larger series.
登录
查看更多内容
影响因子：
11.2
作者：
Frank, NY;Margaryan, A;Frank, MH
通讯作者：
Frank, MH
影响因子：
11.5
作者：
Mehra, Niven;Penning, Maarten;Voest, Emile E.
通讯作者：
Voest, Emile E.
影响因子：
11.2
作者：
Collins, AT;Berry, PA;Maitland, NJ
通讯作者：
Maitland, NJ
影响因子：
64.5
作者：
Kim, CFB;Jackson, EL;Jacks, T
通讯作者：
Jacks, T
影响因子：
8.8
作者：
Maeda, S.;Shinchi, H.;Kurahara, H.;Mataki, Y.;Maemura, K.;Sato, M.;Natsugoe, S.;Aikou, T.;Takao, S.
通讯作者：
Takao, S.